Enzyme replacement therapy (ERT) is effective in prolonging survival and improving cardiomyopathy and motor outcomes in patients with Pompe disease (PD). Factors influencing response to therapy include age at onset, genotype, extent of pathology, and muscle damage at the time of starting treatment.1

CASE REPORTS

We report on two siblings, a sister and brother, with a non-classic infantile variant of PD on ERT for 9 years, and compare their clinical outcome and muscle MRI findings.

Both siblings were heterozygote for two mutations c.572A>G (p.Glu176fsX)/c.525delT (p.Tyr191Cys) of the GAA gene.2 The sister (Patient 1) received the diagnosis at the age of 4 years, because of facial weakness, rhinolalia, limb girdle muscular weakness, walking, climbing, and jumping difficulties, and hyperCPKemia. Echocardiography revealed hypertrophic cardiomyopathy (LVMI 177.8 g/m²). Diagnosis was confirmed by assessment of GAA activity in muscle biopsy, resulting in an undetectable level. The brother (Patient 2) has been evaluated at 7 months of age soon after the diagnosis of his sister. Physical examination was normal, but hyperCPKemia and hypertrophic cardiomyopathy (LVMI 150 g/m²) were recorded. GAA activity in leukocytes was undetectable. Both siblings initiated ERT as compassionate therapy at 4.6 years (Patient 1) and 18 months (Patient 2) of age. Cardiac hypertrophy disappeared within 2 years in Patient 1 and 1 year in Patient 2. ERT has been well tolerated and no increase in anti-rhGAA antibodies has ever been detected.

During long-term follow-up, Patient 2 has maintained a completely normal motor function and at the age of 10 years, he has no signs of myopathy.

Patient 1, now 13 years old, has shown progressive muscular weakness with a marked steppage gait. At the 6-minute walk test, she covered a distance of 480 m. She has never acquired the ability to jump and run. Functional pulmonary test showed a progressive chronic respiratory insufficiency (FEV1 65%).

---

*Correspondence to: Federica Deodato, Unit of Metabolism, Department of Pediatric Medicine, Bambino Gesù Children’s Hospital, Rome, Italy. E-mail: federica.deodato@opbg.net.

ISSN 2214-3599/15/$27.50 © 2015 – IOS Press and the authors. All rights reserved.
This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License.
CONCLUSIONS

These different outcomes in two siblings confirm that an early start of ERT in PD is effective in preventing progression of the disease, in particular of muscle damage.

REFERENCES
